IGC Pharma (IGC) vs Seres Therapeutics (MCRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IGC Pharma is the larger company by market cap ($28.8 million vs $26.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IGC | MCRB |
|---|---|---|
| Share price | $0.2783 | $2.64 |
| Market cap | $28.77M | $26.52M |
| 1-day change | -2.32% | +0.38% |
| YTD return | +1.75% | — |
| 1-year return | -32.17% | — |
| 5-year return | -80.49% | — |
| EPS (TTM) | $-0.07 | $-2.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $0.45 | $29.98 |
| 52-week low | $0.24 | $2.42 |
| Distance from 52-week high | -38.16% | -91.19% |
| Analyst consensus | none | none |
| Avg. price target upside | +2055.95% | +543.94% |
| Average volume | 704.91K | 73.43K |
| Shares outstanding | 103.38M | 10.04M |
| Employees | 70 | 66 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About IGC Pharma
IGC stock →IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
About Seres Therapeutics
MCRB stock →Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
IGC vs MCRB FAQ
Which is bigger, IGC Pharma or Seres Therapeutics?
IGC Pharma (IGC) is larger, with a market capitalization of $28.77M compared with $26.52M for Seres Therapeutics (MCRB).
Are IGC Pharma and Seres Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.